{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:57:58Z","timestamp":1782917878027,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol Exp"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Percutaneous cryoablation (PC) has been incorporated among first-line treatment options for desmoid-type fibromatosis (DF). Loco-regional therapies, including PC, induce tissue changes that may precede measurable tumor shrinkage, thereby limiting the reliability of purely dimensional response criteria. To address this limitation, we compared response evaluation criteria in solid tumors (RECIST) 1.1 and magnetic resonance imaging (MRI)-adapted (M-)RECIST in patients with DF treated with PC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We retrospectively identified all consecutive patients with progressing extra-abdominal DF treated with PC. Responses were assessed with RECIST 1.1 and M-RECIST, the latter relying on T2- and diffusion-weighted imaging, as well as unenhanced and contrast-enhanced T1-weighted imaging, to define residual viable tumor. Non-progression (NPR) and overall response rates (ORR) were defined as the percentage of patients without radiological progression and partial\/complete responses, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-four patients (females\/males, 26\/8) and 37 procedures were identified. RECIST 1.1 and M-RECIST were applicable in 35 and 34 procedures, respectively. At a median follow-up of 15.7 months (interquartile range [IQR] 19.5), RECIST 1.1. Responses were: 10\/35 (28.6%) partial response (PR), 22\/35 (62.9%) stable disease (SD), and 3\/35 (8.6%) progressive disease (PD), with ORR 28.6% and NPR 91.4%. At a median follow-up of 16.0 months (IQR 20.5), M-RECIST responses were: 15\/34 (44.1%) complete response (CR), 12\/34 (35.3%) PR, 4\/34 (11.8%) SD, and 3\/34 (8.8%) PD, with ORR 79.4% and NPR 91.2%. Overall concordance was negligible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>M-RECIST yielded higher NPR\/ORR than RECIST 1.1. These findings pave the way for studies addressing whether this shift in response categorization associates with improved outcomes prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance statement<\/jats:title>\n                    <jats:p>This work provides supporting evidence for the implementation of residual viable disease assessment in evaluating DF responses to PC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>In patients with DF, responses to cryoablation can be characterized using purely dimensional and viability-based criteria.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>RECIST 1.1 and M-RECIST yielded complete agreement for PD.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>M-RECIST may refine response categorization below the progression threshold.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41747-026-00767-2","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:39:56Z","timestamp":1782916796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiologic response assessment in patients with desmoid-type fibromatosis treated with percutaneous cryoablation"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6281-7807","authenticated-orcid":false,"given":"Andrea","family":"Vanzulli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Saggiante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilla Violetta","family":"Sciacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Cascella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Lanocita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Rausa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vitellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Tin\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Palassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pasquali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Giovanni","family":"Casali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Stacchiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Morosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"767_CR1","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/jamaoncol.2024.1805","volume":"10","author":"B Kasper","year":"2024","unstructured":"Kasper B, Baldini EH, Bonvalot S et al (2024) Current management of desmoid tumors: a review. JAMA Oncol 10:1121\u20131128. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1805","journal-title":"JAMA Oncol"},{"key":"767_CR2","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1200\/JCO.2010.33.5489","volume":"29","author":"S Salas","year":"2011","unstructured":"Salas S, Dufresne A, Bui B et al (2011) Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 29:3553\u20133558. https:\/\/doi.org\/10.1200\/JCO.2010.33.5489","journal-title":"J Clin Oncol"},{"key":"767_CR3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/SLA.0000000000005795","volume":"277","author":"ARW Schut","year":"2023","unstructured":"Schut ARW, Timbergen MJM, Nasserinejad K et al (2023) Health-related quality of life of patients with non-intra-abdominal desmoid-type fibromatosis during active surveillance: results of a prospective observational study. Ann Surg 277:877\u2013883. https:\/\/doi.org\/10.1097\/SLA.0000000000005795","journal-title":"Ann Surg"},{"key":"767_CR4","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1245\/s10434-019-07826-6","volume":"26","author":"WJ van Houdt","year":"2019","unstructured":"van Houdt WJ, Husson O, Patel A et al (2019) Outcome of primary desmoid tumors at all anatomic locations initially managed with active surveillance. Ann Surg Oncol 26:4699\u20134706. https:\/\/doi.org\/10.1245\/s10434-019-07826-6","journal-title":"Ann Surg Oncol"},{"key":"767_CR5","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1093\/annonc\/mdx323","volume":"28","author":"B Kasper","year":"2017","unstructured":"Kasper B, Baumgarten C, Garcia J et al (2017) An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)\/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol 28:2399\u20132408. https:\/\/doi.org\/10.1093\/annonc\/mdx323","journal-title":"Ann Oncol"},{"key":"767_CR6","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1002\/cncr.33233","volume":"126","author":"B Kasper","year":"2020","unstructured":"Kasper B, Raut CP, Gronchi A (2020) Desmoid tumors: to treat or not to treat, That is the question. Cancer 126:5213\u20135221. https:\/\/doi.org\/10.1002\/cncr.33233","journal-title":"Cancer"},{"key":"767_CR7","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-21-4205","volume":"28","author":"C Colombo","year":"2022","unstructured":"Colombo C, Fiore M, Grignani G et al (2022) A prospective observational study of active surveillance in primary desmoid fibromatosis. Clin Cancer Res 28:4027\u20134032. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4205","journal-title":"Clin Cancer Res"},{"key":"767_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1158\/1078-0432.CCR-24-2340","volume":"31","author":"C Colombo","year":"2025","unstructured":"Colombo C, Hakkesteegt S, Le Cesne A et al (2025) Active surveillance in patients with extra-abdominal desmoid-type fibromatosis: a pooled analysis of three prospective observational studies. Clin Cancer Res 31:603\u2013610. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2340","journal-title":"Clin Cancer Res"},{"key":"767_CR9","doi-asserted-by":"publisher","first-page":"8653","DOI":"10.1245\/s10434-023-14341-2","volume":"30","author":"S Bonvalot","year":"2023","unstructured":"Bonvalot S, Cozic N, Le Cesne A et al (2023) Initial active surveillance strategy for patients with peripheral sporadic primary desmoid-type fibromatosis: a multicentric phase II observational trial. Ann Surg Oncol 30:8653\u20138659. https:\/\/doi.org\/10.1245\/s10434-023-14341-2","journal-title":"Ann Surg Oncol"},{"key":"767_CR10","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/SLA.0000000000005415","volume":"277","author":"ARW Schut","year":"2023","unstructured":"Schut ARW, Timbergen MJM, Van Broekhoven DLM et al (2023) A nationwide prospective clinical trial on active surveillance in patients with non-intraabdominal desmoid-type fibromatosis: the GRAFITI Trial. Ann Surg 277:689\u2013696. https:\/\/doi.org\/10.1097\/SLA.0000000000005415","journal-title":"Ann Surg"},{"key":"767_CR11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/jso.25597","volume":"120","author":"K Redifer Tremblay","year":"2019","unstructured":"Redifer Tremblay K, Lea WB, Neilson JC et al (2019) Percutaneous cryoablation for the treatment of extra-abdominal desmoid tumors. J Surg Oncol 120:366\u2013375. https:\/\/doi.org\/10.1002\/jso.25597","journal-title":"J Surg Oncol"},{"key":"767_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00270-019-02323-5","volume":"43","author":"A Bouhamama","year":"2020","unstructured":"Bouhamama A, Lame F, Mastier C et al (2020) Local control and analgesic efficacy of percutaneous cryoablation for desmoid tumors. Cardiovasc Intervent Radiol 43:110\u2013119. https:\/\/doi.org\/10.1007\/s00270-019-02323-5","journal-title":"Cardiovasc Intervent Radiol"},{"key":"767_CR13","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jvir.2018.09.033","volume":"30","author":"RR Haroun","year":"2019","unstructured":"Haroun RR, Quencer KB, Erinjeri JP et al (2019) Percutaneous cryoablation of an extra-abdominal desmoid tumor abutting the skin surface and peritoneum. J Vasc Interv Radiol 30:556. https:\/\/doi.org\/10.1016\/j.jvir.2018.09.033","journal-title":"J Vasc Interv Radiol"},{"key":"767_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-016-0848-3","volume":"33","author":"RL Cazzato","year":"2016","unstructured":"Cazzato RL, Garnon J, Ramamurthy N et al (2016) Percutaneous image-guided cryoablation: current applications and results in the oncologic field. Med Oncol 33:140. https:\/\/doi.org\/10.1007\/s12032-016-0848-3","journal-title":"Med Oncol"},{"key":"767_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.2214\/AJR.15.14391","volume":"207","author":"JJ Schmitz","year":"2016","unstructured":"Schmitz JJ, Schmit GD, Atwell TD et al (2016) Percutaneous cryoablation of extraabdominal desmoid tumors: a 10-year experience. AJR Am J Roentgenol 207:190\u2013195. https:\/\/doi.org\/10.2214\/AJR.15.14391","journal-title":"AJR Am J Roentgenol"},{"key":"767_CR16","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1007\/s00270-013-0830-9","volume":"37","author":"M Havez","year":"2014","unstructured":"Havez M, Lippa N, Al-Ammari S et al (2014) Percutaneous image-guided cryoablation in inoperable extra-abdominal desmoid tumors: a study of tolerability and efficacy. Cardiovasc Intervent Radiol 37:1500\u20131506. https:\/\/doi.org\/10.1007\/s00270-013-0830-9","journal-title":"Cardiovasc Intervent Radiol"},{"key":"767_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00256-009-0801-z","volume":"39","author":"JL Kujak","year":"2010","unstructured":"Kujak JL, Liu PT, Johnson GB, Callstrom MR (2010) Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors. Skeletal Radiol 39:175\u2013182. https:\/\/doi.org\/10.1007\/s00256-009-0801-z","journal-title":"Skeletal Radiol"},{"key":"767_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2020.10.035","volume":"143","author":"JE Kurtz","year":"2021","unstructured":"Kurtz JE, Buy X, Deschamps F et al (2021) CRYODESMO-O1: a prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. Eur J Cancer 143:78\u201387. https:\/\/doi.org\/10.1016\/j.ejca.2020.10.035","journal-title":"Eur J Cancer"},{"key":"767_CR19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ejca.2014.11.019","volume":"51","author":"C Colombo","year":"2015","unstructured":"Colombo C, Miceli R, Le P\u00e9choux C et al (2015) Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Eur J Cancer 51:186\u2013192. https:\/\/doi.org\/10.1016\/j.ejca.2014.11.019","journal-title":"Eur J Cancer"},{"key":"767_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104299","volume":"10","author":"A Vanzulli","year":"2025","unstructured":"Vanzulli A, Vigorito R, Buonomenna C et al (2025) Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial. ESMO Open 10:104299. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104299","journal-title":"ESMO Open"},{"key":"767_CR21","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1158\/1078-0432.CCR-12-3796","volume":"19","author":"R Lencioni","year":"2013","unstructured":"Lencioni R (2013) New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma. Clin Cancer Res 19:1312\u20131314. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3796","journal-title":"Clin Cancer Res"},{"key":"767_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM (2010) Modified recist (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132","journal-title":"Semin Liver Dis"},{"key":"767_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet JM, Lencioni R (2020) mRECIST for HCC: performance and novel refinements. J Hepatol 72:288\u2013306. https:\/\/doi.org\/10.1016\/j.jhep.2019.09.026","journal-title":"J Hepatol"},{"key":"767_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/cncr.26255","volume":"118","author":"J Edeline","year":"2012","unstructured":"Edeline J, Boucher E, Rolland Y et al (2012) Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 118:147\u2013156. https:\/\/doi.org\/10.1002\/cncr.26255","journal-title":"Cancer"},{"key":"767_CR25","unstructured":"Gwet KL (2021) Handbook of inter-rater reliability: the definitive guide to measuring the extent of agreement among raters, 5th edn. Gaithersburg"},{"key":"767_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13244-020-00884-5","volume":"11","author":"M Maas","year":"2020","unstructured":"Maas M, Beets-Tan R, Gaubert JY et al (2020) Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice. Insights Imaging 11:83. https:\/\/doi.org\/10.1186\/s13244-020-00884-5","journal-title":"Insights Imaging"},{"key":"767_CR27","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1002\/cncr.27624","volume":"118","author":"S Stacchiotti","year":"2012","unstructured":"Stacchiotti S, Verderio P, Messina A et al (2012) Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer 118:5857\u20135866. https:\/\/doi.org\/10.1002\/cncr.27624","journal-title":"Cancer"},{"key":"767_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1148\/radiol.2512081403","volume":"251","author":"S Stacchiotti","year":"2009","unstructured":"Stacchiotti S, Collini P, Messina A et al (2009) High-grade soft-tissue sarcomas: tumor response assessment\u2014pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 251:447\u2013456. https:\/\/doi.org\/10.1148\/radiol.2512081403","journal-title":"Radiology"},{"key":"767_CR29","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753\u20131759. https:\/\/doi.org\/10.1200\/JCO.2006.07.3049","journal-title":"J Clin Oncol"},{"key":"767_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100170","volume":"6","author":"S Stacchiotti","year":"2021","unstructured":"Stacchiotti S, Miah AB, Frezza AM et al (2021) Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO Open 6:100170. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100170","journal-title":"ESMO Open"},{"key":"767_CR31","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1634\/theoncologist.2013-0114","volume":"19","author":"M Ronot","year":"2014","unstructured":"Ronot M, Bouattour M, Wassermann J et al (2014) Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with Sorafenib. Oncologist 19:394\u2013402. https:\/\/doi.org\/10.1634\/theoncologist.2013-0114","journal-title":"Oncologist"},{"key":"767_CR32","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","volume":"13","author":"SG Armato","year":"2018","unstructured":"Armato SG, Nowak AK (2018) Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (version 1.1). J Thorac Oncol 13:1012\u20131021. https:\/\/doi.org\/10.1016\/j.jtho.2018.04.034","journal-title":"J Thorac Oncol"},{"key":"767_CR33","first-page":"65","volume":"32","author":"S Colangeli","year":"2018","unstructured":"Colangeli S, Parchi P, Andreani L et al (2018) Cryotherapy efficacy and safety as local therapy in surgical treatment of musculoskeletal tumours. A retrospective case series of 143 patients. J Biol Regul Homeost Agents 32:65\u201370","journal-title":"J Biol Regul Homeost Agents"},{"key":"767_CR34","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/SLA.0000000000003073","volume":"271","author":"MR Cassidy","year":"2020","unstructured":"Cassidy MR, Lefkowitz RA, Long N et al (2020) Association of MRI T2 signal intensity with desmoid tumor progression during active observation: a retrospective cohort study. Ann Surg 271:748\u2013755. https:\/\/doi.org\/10.1097\/SLA.0000000000003073","journal-title":"Ann Surg"},{"key":"767_CR35","doi-asserted-by":"publisher","first-page":"W1008","DOI":"10.2214\/AJR.11.6657","volume":"197","author":"AB Shinagare","year":"2011","unstructured":"Shinagare AB, Ramaiya NH, Jagannathan JP et al (2011) A to Z of desmoid tumors. AJR AM J Roentgenol 197:W1008\u2013W1014. https:\/\/doi.org\/10.2214\/AJR.11.6657","journal-title":"AJR AM J Roentgenol"},{"key":"767_CR36","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.crad.2015.04.015","volume":"70","author":"S Otero","year":"2015","unstructured":"Otero S, Moskovic EC, Strauss DC et al (2015) Desmoid-type fibromatosis. Clin Radiol 70:1038\u20131045. https:\/\/doi.org\/10.1016\/j.crad.2015.04.015","journal-title":"Clin Radiol"},{"key":"767_CR37","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.36922\/td.1414","volume":"2","author":"RF Valenzuela","year":"2023","unstructured":"Valenzuela RF, Sierra ED, Canjirathinkal MA et al (2023) Early results in the novel use of contrast-enhanced susceptibility-weighted imaging in the assessment of response and progression in desmoid fibromatosis: a pilot study in a specialized cancer institution. Tumor Discov 2:1414. https:\/\/doi.org\/10.36922\/td.1414","journal-title":"Tumor Discov"},{"key":"767_CR38","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.2214\/AJR.19.22635","volume":"215","author":"A Cromb\u00e9","year":"2020","unstructured":"Cromb\u00e9 A, Kind M, Ray-Coquard I et al (2020) Progressive desmoid tumor: radiomics compared with conventional response criteria for predicting progression during systemic therapy\u2014a multicenter study by the French Sarcoma Group. AJR Am J Roentgenol 215:1539\u20131548. https:\/\/doi.org\/10.2214\/AJR.19.22635","journal-title":"AJR Am J Roentgenol"},{"key":"767_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s41747-025-00559-0","volume":"9","author":"A Vanzulli","year":"2025","unstructured":"Vanzulli A, Sciacqua LV, Patti F et al (2025) Radiomics to predict tumor response to combination chemoradiotherapy in squamous cell carcinoma of the anal canal: a preliminary investigation. Eur Radiol Exp 9:35. https:\/\/doi.org\/10.1186\/s41747-025-00559-0","journal-title":"Eur Radiol Exp"},{"key":"767_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115120","volume":"213","author":"S Pasquali","year":"2024","unstructured":"Pasquali S, Iadecola S, Vanzulli A et al (2024) Radiomic features of primary retroperitoneal sarcomas: a prognostic study. Eur J Cancer 213:115120. https:\/\/doi.org\/10.1016\/j.ejca.2024.115120","journal-title":"Eur J Cancer"},{"key":"767_CR41","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3390\/cancers13081929","volume":"13","author":"JC Peeken","year":"2021","unstructured":"Peeken JC, Neumann J, Asadpour R et al (2021) Prognostic assessment in high-grade soft-tissue sarcoma patients: a comparison of semantic image analysis and radiomics. Cancers (Basel) 13:1929. https:\/\/doi.org\/10.3390\/cancers13081929","journal-title":"Cancers (Basel)"},{"key":"767_CR42","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/brain\/awab340","volume":"145","author":"G Li","year":"2022","unstructured":"Li G, Li L, Li Y et al (2022) An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas. Brain 145:1151\u20131161. https:\/\/doi.org\/10.1093\/brain\/awab340","journal-title":"Brain"},{"key":"767_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3389\/fncom.2019.00058","volume":"13","author":"AFI Osman","year":"2019","unstructured":"Osman AFI (2019) A multi-parametric MRI-based radiomics signature and a practical ML model for stratifying glioblastoma patients based on survival toward precision oncology. Front Comput Neurosci 13:58. https:\/\/doi.org\/10.3389\/fncom.2019.00058","journal-title":"Front Comput Neurosci"},{"key":"767_CR44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1148\/radiol.2021210109","volume":"302","author":"T Wang","year":"2022","unstructured":"Wang T, She Y, Yang Y et al (2022) Radiomics for survival risk stratification of clinical and pathologic stage IA pure-solid non-small cell lung cancer. Radiology 302:425\u2013434. https:\/\/doi.org\/10.1148\/radiol.2021210109","journal-title":"Radiology"},{"key":"767_CR45","doi-asserted-by":"publisher","unstructured":"Verma V, Simone CB, Krishnan S et al (2017) The rise of radiomics and implications for oncologic management. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djx055","DOI":"10.1093\/jnci\/djx055"},{"key":"767_CR46","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1148\/rg.2021210037","volume":"41","author":"JD Shur","year":"2021","unstructured":"Shur JD, Doran SJ, Kumar S et al (2021) Radiomics in oncology: a practical guide. Radiographics 41:1717\u20131732. https:\/\/doi.org\/10.1148\/rg.2021210037","journal-title":"Radiographics"}],"container-title":["European Radiology Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41747-026-00767-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41747-026-00767-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41747-026-00767-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:40:08Z","timestamp":1782916808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41747-026-00767-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["767"],"URL":"https:\/\/doi.org\/10.1186\/s41747-026-00767-2","relation":{},"ISSN":["2509-9280"],"issn-type":[{"value":"2509-9280","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (INT 156\/25).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data have been anonymized. Figures do not contain sensitive data and cannot be traced back to individual patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AG received honoraria from SpringWorks. None of the other authors have reported CI directly related to this manuscript. AV is a member of the Scientific Editorial Board of European Radiology Experimental and as such did not participate in the selection nor review processes for this article. Unrelated CI: SS reports honoraria from Aadi, Bayer, Boehringer, Deciphera, Daiichi Sankyo, Merk Serono, Novartis, Glaxo Smith Kline (GSK), Orion, Parabilis, PharmaMar; participation on a Data Safety Monitoring Board or Advisory Board for Bayer, Bavarian Nordic, Deciphera, Eli Lilly, Daiichi Sankyo, GSK, Ikena, Maxivax, Novartis, Pharmamar, Servier; institutional research funding from Amgen Dompe, Advenchen, Bayer, Blueprint Medicines, Deciphera, Eli Lilly, Epizyme, Daiichi Sankyo, GSK, Hutchinson MediPharma International Inc, Inhibrix, Karyopharm, Novartis, Pfizer, PharmaMar, SpringWorks. AG reports honoraria from Novartis, Pfizer, Bayer, Lilly, Boehringer Ingelheim, Deciphera, PharmaMar; institutional grants from Nanobiotix and PharmaMar. CC reports honoraria from Parabilis. All the other Authors reported no unrelated CI.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}